{"id":653109,"date":"2023-05-25T19:32:02","date_gmt":"2023-05-25T19:32:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=653109"},"modified":"2023-05-25T19:32:02","modified_gmt":"2023-05-25T19:32:02","slug":"prostate-health-market-is-expected-to-reach-589-billion-by-2028-an-exclusive-market-research-report-by-lucintel","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/prostate-health-market-is-expected-to-reach-589-billion-by-2028-an-exclusive-market-research-report-by-lucintel_653109.html","title":{"rendered":"Prostate Health Market is expected to reach $58.9 Billion by 2028 – An exclusive market research report by Lucintel"},"content":{"rendered":"
\n
\"Prostate<\/a><\/div>\n
\n
Trends and Forecast for the Global prostate health market<\/div>\n<\/div>\n<\/div>\n
Trends, opportunities, and forecast for the global prostate health market from 2017 to 2028 by disease indication (prostate cancer, prostatitis, alpha blockers, benign prostate hyperplasia, and others), treatment outlook (cytotoxic agents, hormone ADT, AR directed therapies, PARP inhibitors, and others), and distribution channel (pharmacy, e-commerce stores, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)<\/div>\n

Lucintel’s latest market report analyzed that prostate health<\/a> provides attractive opportunities in pharmacies and e-commerce stores. The prostate health market is expected to reach $58.9 billion by 2028 with a CAGR of 9.1%. In this market, prostate cancer is the largest segment by disease indication, whereas e-commerce store is largest by disease indication.<\/p>\n

Based on disease indication, the prostate health market is segmented into prostate cancer, prostatitis, alpha blockers, benign prostate hyperplasia, and others. The prostate cancer segment accounted for the largest share of the market in 2023 and is expected to register the highest CAGR during the forecast period, due to because augmenting cancer cases has influenced the usage of immunotherapies to inhibit prostate cancer cells from spreading. Also, hormone therapy is generally used to effectively treat cancer at the initial stage.<\/p>\n

Browse in-depth TOC on “Prostate Health Market”<\/p>\n

100 – Figures\/Tables<\/p>\n

150 – Pages<\/p>\n

The Prostate Health Market is marked by the presence of several big and small players. Some of the prominent players offering prostate health include Eli Lilly and Company, Pfizer, Merck & Co., Abbott, Endo Pharmaceuticals, GlaxoSmithKline PLC, Siemens Healthcare, Amgen, and AstraZeneca.<\/p>\n

Request Sample Report: <\/strong>https:\/\/www.lucintel.com\/prostate-health-market.aspx<\/a><\/p>\n

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link helpdesk@lucintel.com<\/a>.<\/p>\n

About Lucintel<\/strong><\/p>\n

Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com<\/a>.<\/p>\n

Roy Almaguer<\/em>Lucintel Dallas, Texas, USA Email: roy.almaguer@lucintel.com  Tel. 972.636.5056<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Lucintel<\/a>
Contact Person:<\/strong> Roy Almaguer
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 972.636.5056
Address:<\/strong>8951 Cypress Waters Blvd., Suite 160
City:<\/strong> Dallas
State:<\/strong> TEXAS
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.lucintel.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Trends and Forecast for the Global prostate health market Trends, opportunities, and forecast for the global prostate health market from 2017 to 2028 by disease indication (prostate cancer, prostatitis, alpha blockers, benign prostate hyperplasia, and others), treatment outlook (cytotoxic agents, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,416],"tags":[],"class_list":["post-653109","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/653109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=653109"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/653109\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=653109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=653109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=653109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}